Canadian News

Monday, January 15, 2018

Servier Canada and the New Brunswick Health Research Foundation announce the creation of the Servier-New Brunswick Cardiac Health Improvement Fund (CHIF)

Wednesday, January 10, 2018

Servier and Treventis begin strategic research partnership in neurodegenerative diseases

Friday, December 15, 2017

Once-Daily Oral Anticoagulant LIXIANA(edoxaban) met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Thursday, November 23, 2017

Servier Canada establishes a new partnership with CQDM to fund a diabetes research project.

Friday, November 10, 2017

Servier Canada announces the launch of VENIXXA, an over-the-counter oral treatment to relieve signs and symptoms of chronic venous disease and hemorrhoids.

Tuesday, June 20, 2017

Servier Canada, Government of Alberta, and the University Hospital Foundation announce the formation of the Servier Alberta Innovation in Health Fund (SAIHF)

Wednesday, May 3, 2017
ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation was initiated
Monday, April 3, 2017
SERVIER CANADA Announces New Toronto Offices
Friday, March 31, 2017
ELIMINATE-AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation was initiated.
Tuesday, February 7, 2017

Servier announces an increase in turnover for 2015-2016. Growth bolstered by strong international performance

Tuesday, January 10, 2017

Health Canada approves new heart failure treatment LANCORA to reduce mortality and hospitalizations

Wednesday, December 7, 2016

GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis 

Wednesday, November 9, 2016

Once-Daily Anticoagulant LIXIANA® (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism

Thursday, October 20, 2016

New compound shows promise in treating multiple human cancers

Monday, September 26, 2016

$21 Million Investment in Québec Biotech Start-up to Develop a Treatment for Venous Lower Limb Ulcers

Thursday, September 1, 2016

Amgen and Servier extend omecamtiv mecarbil collaboration in chronic heart failure 

Monday, June 27, 2016

Servier Canada is pleased to announce the signing of a strategic agreement with Daiichi Sankyo Co., Limited

Friday, January 29, 2016

Viacoram now approved in Canada as a new first line treatment in hypertension

Tuesday, January 12, 2016

Spectrum Pharmaceuticals signs a strategic partnership with Servier Canada

Thursday, November 19, 2015

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19

Thursday, November 13, 2014
INTARCIA and SERVIER sign EX-U.S. partnership for ITCA 650 in diabetes
Friday, October 10, 2014
Friday, September 19, 2014
SERVIER and CTI BIOPHARMA announce exclusive license and collaboration agreement to develop and commercialize PIXUVRI
Friday, April 18, 2014
Servier Research Group announces the death of President-Founder Dr. Jacques Servier
Wednesday, April 16, 2014
Servier: one of France’s most remarkable industrial undertakings
Friday, February 14, 2014
Servier Canada invests $10M in two research projects supported by the Partnership Fund for an Innovative, Healthy Quebec